{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:17:34Z","timestamp":1791605854377,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.ejps.2023.106448","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T05:57:02Z","timestamp":1681451822000},"page":"106448","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1\/Fc fusion protein after a single ascending dose in Chinese healthy subjects"],"prefix":"10.1016","volume":"185","author":[{"given":"Jiangli","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0017-4364","authenticated-orcid":false,"given":"Mai","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huikun","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoxi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.ejps.2023.106448_bib0001","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ejps.2023.106448_bib0002","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.ejps.2023.106448_bib0003","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/ijo.2013.162","article-title":"Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults","volume":"38","author":"van Can","year":"2014","journal-title":"Int. J. Obes. (Lond)"},{"issue":"8","key":"10.1016\/j.ejps.2023.106448_bib0004","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2337\/dc13-2761","article-title":"Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in Type 2 diabetes in a randomized controlled Trial (AWARD-5)","volume":"37","author":"Nauck","year":"2014","journal-title":"Diabetes. Care"},{"issue":"9683","key":"10.1016\/j.ejps.2023.106448_bib0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejps.2023.106448_bib0006","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet. Diabetes. Endocrinol"},{"issue":"8","key":"10.1016\/j.ejps.2023.106448_bib0007","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet. Diabetes. Endocrinol"},{"key":"10.1016\/j.ejps.2023.106448_bib0008","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lanc. Diabetes. Endocrinol"},{"issue":"4","key":"10.1016\/j.ejps.2023.106448_bib0009","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"10157","key":"10.1016\/j.ejps.2023.106448_bib0010","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomized placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.ejps.2023.106448_bib0011","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med"},{"issue":"13","key":"10.1016\/j.ejps.2023.106448_bib0012","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"10193","key":"10.1016\/j.ejps.2023.106448_bib0013","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomized placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.ejps.2023.106448_bib0014","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/JXX.0000000000000661","article-title":"GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: clinical evidence and best practice","volume":"34","author":"Coke","year":"2022","journal-title":"J. Am. Assoc. Nurse. Pract"},{"issue":"suppl1","key":"10.1016\/j.ejps.2023.106448_bib0015","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc20-S010","article-title":"Cardiovascular disease and risk management: standards of Medical Care in Diabetes-2020","volume":"43","author":"Association","year":"2020","journal-title":"Diabetes. Care"},{"issue":"2","key":"10.1016\/j.ejps.2023.106448_bib0016","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"ESC scientific document group. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart. J"},{"issue":"suppl 1","key":"10.1016\/j.ejps.2023.106448_bib0017","first-page":"S98","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of Medical Care in Diabetes-2020","volume":"43","year":"2020","journal-title":"Diabetes. Care"},{"issue":"4","key":"10.1016\/j.ejps.2023.106448_bib0018","first-page":"315","article-title":"Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)","volume":"13","year":"2021","journal-title":"Zhonghua. Tang. Niao. Bing. Za. Zhi"},{"issue":"6","key":"10.1016\/j.ejps.2023.106448_bib0019","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/dme.12651","article-title":"Adherence to diabetes medication: a systematic review","volume":"32","author":"Krass","year":"2015","journal-title":"Diabet. Med"},{"issue":"8","key":"10.1016\/j.ejps.2023.106448_bib0020","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1016\/j.apsb.2021.05.002","article-title":"A review of existing strategies for designing long-acting parenteral formulations: focus on underlying mechanisms, and future perspectives","volume":"11","author":"Shi","year":"2021","journal-title":"Acta. Pharm. Sin. B"},{"key":"10.1016\/j.ejps.2023.106448_bib0021","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2018.07.009","article-title":"Battle of GLP-1 delivery technologies","volume":"130","author":"Yu","year":"2018","journal-title":"Adv. Drug. Deliv. Rev"},{"issue":"Supplement_1","key":"10.1016\/j.ejps.2023.106448_bib0022","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2337\/db19-114-LB","article-title":"GX-G6, a novel long-acting glucagon-like peptide receptor agonist: result of Phase I study in healthy volunteers","volume":"68","author":"Byun","year":"2019","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.ejps.2023.106448_bib0023","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/pst.326","article-title":"Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion","volume":"8","author":"Hummel","year":"2009","journal-title":"Pharm. Stat"},{"issue":"8","key":"10.1016\/j.ejps.2023.106448_bib0024","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/dmrr.2810","article-title":"Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program","volume":"32","author":"Jendle","year":"2016","journal-title":"Diabetes Metab. Res. Rev"},{"issue":"1","key":"10.1016\/j.ejps.2023.106448_bib0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/dia.2014.0188","article-title":"Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"17","author":"Sun","year":"2015","journal-title":"Diabetes Technol. Ther"},{"issue":"3","key":"10.1016\/j.ejps.2023.106448_bib0026","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","article-title":"Effects of GLP-1 on appetite and weight","volume":"15","author":"Shah","year":"2014","journal-title":"Rev. Endocr. Metab. Disord"},{"issue":"9","key":"10.1016\/j.ejps.2023.106448_bib0027","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1111\/dom.13358","article-title":"Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes","volume":"20","author":"Petri","year":"2018","journal-title":"Diabetes. Obes. Metab"},{"issue":"5","key":"10.1016\/j.ejps.2023.106448_bib0028","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.2337\/db10-0474","article-title":"Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans","volume":"60","author":"Nauck","year":"2011","journal-title":"Diabetes"},{"key":"10.1016\/j.ejps.2023.106448_bib0029","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1463-1326.2010.01330.x","article-title":"Liraglutide \u2013 overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes","volume":"13","author":"Davies","year":"2011","journal-title":"Diabetes Obes. Metab"},{"key":"10.1016\/j.ejps.2023.106448_bib0030","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc11-1107","article-title":"Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study","volume":"35","author":"Russell-Jones","year":"2012","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.ejps.2023.106448_bib0031","first-page":"A294","article-title":"Exenatide once weekly did not affect corrected QT interval in patients with type 2 diabetes","volume":"60","author":"Sager","year":"2011","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.ejps.2023.106448_bib0032","first-page":"A270","article-title":"Lixisenatide (Lyxumia\u00ae) has no effect on QTc interval in healthy subjects: a thorough QTc study","volume":"65","author":"Tillner","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.ejps.2023.106448_bib0033","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13300-014-0055-1","article-title":"Albiglutide does not prolong QTc interval in healthy subjects: a thorough ECG study","volume":"5","author":"Darpo","year":"2014","journal-title":"Diabetes. Ther"},{"key":"10.1016\/j.ejps.2023.106448_bib0034","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/HYPERTENSIONAHA.114.03062","article-title":"Effects of the once weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus","volume":"64","author":"Ferdinand","year":"2014","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.ejps.2023.106448_bib0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-019-0871-8","article-title":"Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial","volume":"18","author":"Leiter","year":"2019","journal-title":"Cardiovasc. Diabetol"},{"issue":"10","key":"10.1016\/j.ejps.2023.106448_bib0036","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/jamacardio.2020.1966","article-title":"Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review","volume":"5","author":"Honigberg","year":"2020","journal-title":"JAMA. Cardiol"},{"issue":"Supplement_1","key":"10.1016\/j.ejps.2023.106448_bib0037","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes\u20142022","volume":"45","year":"2022","journal-title":"Diabetes. Care"},{"key":"10.1016\/j.ejps.2023.106448_bib0038","first-page":"74","article-title":"A preliminary survey on urinary \u03b22-microglobulin of 60 healthy adults","volume":"1","author":"Huang","year":"1983","journal-title":"Chin. J. Ind. Hyg. Occup. Med"},{"issue":"4","key":"10.1016\/j.ejps.2023.106448_bib0039","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/occmed\/44.4.195","article-title":"Urinary \u03b22- and \u03b11-microglobulin levels in normal subjects in Singapore","volume":"44","author":"Gan","year":"1994","journal-title":"Occup. Med. (Lond)"},{"key":"10.1016\/j.ejps.2023.106448_bib0040","unstructured":"American Conference of Governmental Industrial Hygienists Inc. 2023 Cadmium in documentation of the threshold limit values and biological exposure indices, 6th edition, volume 3. Cincinnati, Ohio: American."},{"key":"10.1016\/j.ejps.2023.106448_bib0041","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mole. Metabol."},{"key":"10.1016\/j.ejps.2023.106448_bib0042","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1007\/s00125-017-4289-0","article-title":"Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial","volume":"60","author":"Kapitza","year":"2017","journal-title":"Diabetologia"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723000787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098723000787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:06:52Z","timestamp":1760530012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098723000787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":42,"alternative-id":["S0928098723000787"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106448","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1\/Fc fusion protein after a single ascending dose in Chinese healthy subjects","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2023.106448","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106448"}}